查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2046171

臨床前影像市場－全球產業規模、佔有率、趨勢、機會、預測：依影像方式、應用、最終用戶、地區和競爭格局分類，2021-2031年

Preclinical Imaging Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Modality, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球臨床前影像市場預計將從 2025 年的 57.7 億美元大幅成長至 2031 年的 83.1 億美元，複合年成長率為 6.27%。

該市場利用磁振造影（MRI）、電腦斷層掃描（CT）和正子斷層掃描（PET）等技術，對小型動物模型中的生理和病理過程進行可視化和量化，從而推進藥物研發和疾病研究。其主要成長要素動力源自於對非侵入性縱向研究日益成長的需求，這符合倫理指南，既能提高轉化數據的準確性，又能減少動物樣本量。此外，對藥物發現研究的大量投資，尤其是在腫瘤學和神經病學等領域，也是推動這些體內觀察技術應用的關鍵因素。儘管成長勢頭強勁，但引進和運行先進的高解析度多模態設備的高昂成本仍然是一大障礙，往往限制了小規模研究機構的使用。然而，生命科學領域的整​​體資金環境依然穩健，為這些技術的應用提供了穩定的基礎。例如，根據歐洲製藥廠商聯合會（EFPIA）的數據，預計到2025年，歐洲製藥業將在研發方面投入約550億歐元，這凸顯了對檢驗工具的持續投入，從而推動了市場需求。

市場概覽
預測期 2027-2031
市場規模：2025年 57.7億美元
市場規模：2031年 83.1億美元
複合年成長率：2026-2031年 6.27%
成長最快的細分市場 光聲成像系統
最大的市場 北美洲

市場促進因素

製藥業研發投入的不斷成長是推動臨床前影像市場擴張的主要動力。隨著藥物研發過程日益複雜，領先企業正大力投資早期檢驗，旨在確認分子在進入人體臨床試驗前的有效性。研發投入的顯著成長直接推動了高精度成像設備的應用，而這些設備對於嚴格的安全性和有效性評估至關重要。例如，根據 Fierce Biotech 2025 年 3 月報道，強生公司在 2024 年將研發投資擴大至約 171 億美元。這凸顯了整個產業積極的投資策略，並確保了對關鍵檢驗工具的穩定需求，這些工具旨在降低藥物研發過程中的失敗率。慢性病盛行率的上升進一步加速了這一市場趨勢，因為它需要進行更廣泛的動物模型研究以進行轉化研究。在腫瘤學、神經病學和心臟病學等領域，迫切需要了解病理機制，這迫使研究機構採用非侵入性影像技術來持續監測疾病進展和治療反應。美國癌症協會在2025年1月的報告中預測，到2025年美國將新增超過200萬例癌症病例，凸顯了癌症疾病負擔之重，這將加速治療方法的研發進程。為了支持這個蓬勃發展的研究生態系統，各大儀器製造商都在維持相當可觀的業務規模。例如，布魯克公司在2025年11月的財報中公佈了8.605億美元的季度銷售額，顯示其生命科學儀器業務的商業活動異常活躍。

市場挑戰

高解析度多模態系統高昂的初始成本和持續營運成本是全球臨床前成像市場成長的一大障礙。這些先進的成像系統需要大量的初始投資，以及持續的維護和專業人員配備預算。這種情況對規模小規模的研究機構和學術機構的影響尤其嚴重，因為它們通常財務柔軟性有限。在資金籌措週期縮減或申請津貼難度加大的時期，這些機構採用關鍵成像技術的能力會立即受到限制，往往導致採購延遲，並繼續依賴低效、過時的設備。公共資金的削減進一步加劇了這種財務負擔，而公共資金歷來是設備採購的重要收入來源。例如，美國大學協會 (AAU) 指出，聯邦研究津貼將在 2025 年大幅下降，其中美國國立衛生研究院 (NIH) 的津貼將比歷史平均下降 29%。可用資金的大幅減少將使目標客戶群主要局限於資金雄厚的製藥公司，從而限制整個科學界的採用，直接阻礙市場成長潛力。

市場趨勢

人工智慧 (AI) 和機器學習在自動化影像分析中的融合，正從根本上改變臨床前工作流程，將研究重點從定性觀察轉向定量、高通量的表現型分析。與容易出現偏差的傳統人工判讀不同，AI 演算法能夠從海量資料集中無偏地提取形態特徵，有效地將影像分析提升為藥物發現中的一級篩檢方法。 Recursion Pharmaceuticals 等公司正是這種轉變為「工業化生物學」的典範，該公司利用 AI 驅動的表現型組學來解讀生物學圖譜，並加速治療方法的檢驗。該公司在 2025 年 2 月的財報中公佈了 5,880 萬美元的全年營收，反映出高度依賴自動化大規模影像資料集的電腦輔助藥物發現平台正日益被商業性接受。混合和多模態成像平台的融合代表著一項關鍵的技術進步，使研究人員能夠在單次實驗中將功能性分子訊號與精確的解剖結構關聯起來。這一趨勢透過整合光學成像和微型CT、或PET和MRI等互補技術，克服了單一成像方式的局限性，在提供全面生理資訊的同時，最大限度地減少了動物操作和麻醉壓力。領先的儀器製造商正在積極拓展這些混合產品線，以滿足轉化醫學複雜的數據需求。例如，Revvity在2025年1月的財報中宣布，年收入達約27.6億美元。這一數字得益於該公司專注於專業診斷和生命科學解決方案的策略，包括IVIS SpectrumCT系列等先進的多模態系統。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球臨床前影像市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依影像方式（光學影像系統、核子醫學影像系統、微型磁振造影、微型超音波、微型電腦斷層掃描、光聲影像系統等）
    • 按應用領域（研發、藥物發現）
    • 按最終用戶（生物技術和製藥公司、學術和研究機構、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美臨床前影像市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲臨床前影像市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區臨床前影像市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲臨床前影像市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲臨床前影像市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球臨床前影像市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Aspect Imaging Ltd
  • Bruker Corporation
  • Fujifilm Holdings Corporation
  • Mediso Ltd
  • MR Solutions Ltd
  • PerkinElmer Inc.
  • United Imaging Healthcare Co. Ltd
  • AXT PTY LTD
  • Advanced Molecular Vision, Inc.
  • IVIM Technology Corp

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16126

The Global Preclinical Imaging Market is projected to expand significantly, rising from USD 5.77 Billion in 2025 to USD 8.31 Billion by 2031, demonstrating a compound annual growth rate of 6.27%. This market involves visualizing and quantifying physiological and pathological processes in small animal models using technologies such as MRI, CT, and PET to advance drug development and disease research. Its primary growth is fueled by the escalating demand for non-invasive longitudinal studies, which align with ethical guidelines to reduce animal cohort sizes while simultaneously enhancing the precision of translational data. Moreover, substantial capital allocation towards pharmaceutical discovery, particularly in areas like oncology and neurology, serves as a key impetus for the adoption of these in vivo observation technologies.Despite its positive growth trajectory, the market faces a considerable hurdle due to the high acquisition and operational expenses associated with advanced high-resolution multi-modal instrumentation, which often restricts access for smaller research facilities. Nevertheless, the broader financial landscape for the life sciences sector remains robust, providing a stable foundation for the procurement of such technologies. For instance, in 2025, the pharmaceutical industry invested an estimated €55 billion in research and development across Europe, according to the European Federation of Pharmaceutical Industries and Associations, highlighting the sustained financial support for demand-driving validation tools.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.77 Billion
Market Size 2031USD 8.31 Billion
CAGR 2026-20316.27%
Fastest Growing SegmentPhotoacoustic Imaging Systems
Largest MarketNorth America

Market Driver

Increased research and development expenditure within the pharmaceutical sector acts as a principal driver for the expansion of the preclinical imaging market. As the process of drug discovery grows more intricate, leading pharmaceutical companies are dedicating substantial financial resources to early-stage validation, aiming to confirm molecule viability before progression to human clinical trials. This significant increase in spending directly stimulates the acquisition of high-fidelity imaging instrumentation, which is essential for rigorous safety and efficacy assessments. For example, Johnson & Johnson escalated its research and development investment to approximately $17.1 billion in 2024, as reported by Fierce Biotech in March 2025, underscoring the aggressive investment strategies prevalent across the industry, which ensures consistent demand for critical validation tools designed to lower attrition rates in drug development.The escalating prevalence of chronic diseases further strengthens the market's upward trajectory by necessitating more extensive animal model studies for translational research. The urgent requirement to comprehend pathological mechanisms in fields such as oncology, neurology, and cardiology compels research institutions to employ non-invasive imaging for continuous monitoring of disease progression and treatment responses. The American Cancer Society projected over 2 million new cancer cases in the United States in 2025, as noted in its January 2025 report, highlighting the critical disease burden that accelerates therapeutic discovery efforts. To support this intensive research ecosystem, major instrument providers maintain considerable operational scales; for instance, Bruker Corporation reported quarterly revenues of $860.5 million in its November 2025 financial results, signifying the substantial commercial activity underpinning life sciences instrumentation.

Market Challenge

The prohibitive acquisition and ongoing operational costs linked with high-resolution multi-modal instrumentation present a significant impediment to the growth of the global preclinical imaging market. These sophisticated imaging systems demand substantial initial capital investment along with considerable recurrent budgets for maintenance and specialized staff. This situation disproportionately impacts smaller research organizations and academic institutions that typically possess limited financial flexibility. During periods of reduced funding cycles or tighter grant availability, these entities often find their capacity to acquire essential imaging technology immediately constrained, leading to delayed purchases and continued reliance on older, less efficient modalities.This financial burden is further intensified by recent reductions in public funding, which traditionally serves as a vital revenue source for equipment procurement. For instance, the Association of American Universities noted a sharp decline in federal research awards in 2025, with National Institutes of Health awards decreasing by 29 percent compared to historical averages. Such a substantial decrease in available capital directly hinders the market's growth potential by confining the accessible customer base primarily to well-capitalized pharmaceutical entities, thereby restricting broader adoption rates throughout the scientific community.

Market Trends

The integration of Artificial Intelligence and Machine Learning for automated image analysis is fundamentally transforming preclinical workflows, shifting the focus from qualitative observation to quantitative, high-throughput phenotyping. Unlike conventional manual interpretation, which is susceptible to variability, AI algorithms now facilitate the unbiased extraction of morphological features across vast datasets, effectively elevating imaging to a primary screening modality in drug discovery. This move towards industrialized biology is well-illustrated by companies such as Recursion Pharmaceuticals, which utilizes AI-enabled phenomics to decipher biological maps and accelerate therapeutic validation; the company reported full-year revenue of $58.8 million in its February 2025 financial results, reflecting the increasing commercial acceptance of computational drug discovery platforms heavily dependent on automated, large-scale imaging datasets.The convergence of hybrid and multimodal imaging platforms represents a crucial technological advancement, enabling researchers to correlate functional molecular signals with precise anatomical structures within a single experimental session. This trend addresses the limitations of individual modalities by integrating complementary technologies, such as optical imaging with micro-CT or PET with MRI, to offer comprehensive physiological insights while simultaneously minimizing animal handling and anesthesia-induced stress. Leading instrument manufacturers are actively expanding these hybrid portfolios to satisfy the complex data requirements of translational medicine. For example, Revvity reported annual revenue of approximately $2.76 billion in its January 2025 financial results, a figure supported by its strategic emphasis on specialized diagnostics and life sciences solutions, including advanced multimodal systems like the IVIS SpectrumCT series.

Key Market Players

  • Aspect Imaging Ltd
  • Bruker Corporation
  • Fujifilm Holdings Corporation
  • Mediso Ltd
  • MR Solutions Ltd
  • PerkinElmer Inc.
  • United Imaging Healthcare Co. Ltd
  • AXT PTY LTD
  • Advanced Molecular Vision, Inc.
  • IVIM Technology Corp

Report Scope

In this report, the Global Preclinical Imaging Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Preclinical Imaging Market, By Modality

  • Optical Imaging Systems
  • Nuclear Imaging Systems
  • Micro-MRI
  • Micro-ultrasound
  • Micro-CT
  • Photoacoustic Imaging Systems
  • Other

Preclinical Imaging Market, By Application

  • Research and Development
  • Drug Discovery

Preclinical Imaging Market, By End User

  • Biotechnology & Pharmaceutical Companies
  • Academic & Research Institutes
  • Others

Preclinical Imaging Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Preclinical Imaging Market.

Available Customizations:

Global Preclinical Imaging Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Preclinical Imaging Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Modality (Optical Imaging Systems, Nuclear Imaging Systems, Micro-MRI, Micro-ultrasound, Micro-CT, Photoacoustic Imaging Systems, Other)
    • 5.2.2. By Application (Research and Development, Drug Discovery)
    • 5.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutes, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Preclinical Imaging Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Modality
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Preclinical Imaging Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Modality
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Preclinical Imaging Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Modality
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Preclinical Imaging Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Modality
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Preclinical Imaging Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Modality
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Preclinical Imaging Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Modality
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. France Preclinical Imaging Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Modality
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Preclinical Imaging Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Modality
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Preclinical Imaging Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Modality
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Preclinical Imaging Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Modality
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia Pacific Preclinical Imaging Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Modality
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Preclinical Imaging Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Modality
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Preclinical Imaging Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Modality
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Preclinical Imaging Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Modality
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Preclinical Imaging Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Modality
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Preclinical Imaging Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Modality
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. Middle East & Africa Preclinical Imaging Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Modality
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Preclinical Imaging Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Modality
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Preclinical Imaging Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Modality
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Preclinical Imaging Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Modality
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. South America Preclinical Imaging Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Modality
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Preclinical Imaging Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Modality
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Preclinical Imaging Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Modality
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Preclinical Imaging Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Modality
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Preclinical Imaging Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Aspect Imaging Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bruker Corporation
  • 15.3. Fujifilm Holdings Corporation
  • 15.4. Mediso Ltd
  • 15.5. MR Solutions Ltd
  • 15.6. PerkinElmer Inc.
  • 15.7. United Imaging Healthcare Co. Ltd
  • 15.8. AXT PTY LTD
  • 15.9. Advanced Molecular Vision, Inc.
  • 15.10. IVIM Technology Corp

16. Strategic Recommendations

17. About Us & Disclaimer